^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GnRH antagonist

    Related drugs:
    1d
    Role of Menopause in Thermoregulation (clinicaltrials.gov)
    P4, N=24, Recruiting, Penn State University | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial primary completion date
    5d
    TASUC-Neo: Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant (clinicaltrials.gov)
    P1, N=2, Terminated, Brown University | N=32 --> 2 | Trial completion date: Jan 2032 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Jul 2025; Principal Investigator left institution
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    AR (Androgen receptor)
    |
    AR positive
    |
    cisplatin • gemcitabine • Firmagon (degarelix)
    8d
    Debio 4228-201: A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Debiopharm International SA | Recruiting --> Active, not recruiting
    Enrollment closed
    14d
    Insights on Medical Therapy for Uterine Fibroids: A Review. (PubMed, Adv Ther)
    Oral GnRH antagonists, which include elagolix, relugolix, and linzagolix, signify a substantial progression, providing rapid and reversible suppression of ovarian hormone synthesis with dose-dependent effects and enhanced convenience. Innovative treatment modalities that target nonhormonal mechanisms, such as extracellular matrix remodeling, angiogenesis, and gene modulation, provide promising prospects for future uterus-sparing interventions. This narrative review evaluates the current and advancing landscape of medical therapies for uterine fibroids, presenting evidence-based perspectives to inform clinical decision-making within an increasingly personalized therapeutic context.
    Review • Journal
    |
    PGR (Progesterone receptor)
    |
    Orgovyx (relugolix) • Yselty (linzagolix)
    29d
    A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Antev Ltd.
    New P2 trial
    1m
    Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer. (PubMed, J Immunother Cancer)
    In this first stage of a pilot study that awaits confirmation with larger numbers of patients, our results suggest that vaccination targeting AR given prior to androgen deprivation therapy might improve outcome for patients with high-risk prostate cancer. Contrary to our initial hypothesis, this was not improved with the addition of PD-1 blockade, possibly due to the activation of regulatory CD4+T cells.
    Journal
    |
    AR (Androgen receptor) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Firmagon (degarelix) • MVI-118
    1m
    A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (clinicaltrials.gov)
    P3, N=333, Recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Cetrotide (cetrorelix)
    1m
    NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, M.D. Anderson Cancer Center | N=36 --> 6 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    Firmagon (degarelix)
    1m
    REDI-CaP (Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients). Innovative Management of Patients with Unfavorable Intermediate-Risk Prostate Cancer: a Special Focus on Quality of Life and Erectile Function Recovery (2025-521170-33-00)
    P1/2, N=50, Recruiting, IRCCS Istituto Nazionale Tumori Fondazione Pascale | Not yet recruiting --> Recruiting
    Enrollment open • HEOR
    |
    Orgovyx (relugolix)
    1m
    A Clinical Study of KLH-2109 in Patients With Endometriosis (clinicaltrials.gov)
    P3, N=288, Active, not recruiting, Kissei Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    leuprolide acetate for depot suspension • Yselty (linzagolix)
    1m
    RELAX: Relugolix for Endometriosis Associated Pain (clinicaltrials.gov)
    P=N/A, N=33, Not yet recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    New trial • Real-world evidence
    |
    Orgovyx (relugolix)
    2ms
    REVELUTION: RElugolix VErsus LeUprolide Cardiac Trial (clinicaltrials.gov)
    P2, N=94, Active, not recruiting, Emory University | Trial completion date: Dec 2025 --> Oct 2026
    Trial completion date
    |
    Orgovyx (relugolix) • leuprolide acetate for depot suspension